Telomir Pharmaceuticals, INC. (TELO) — 10-Q Filings

All 10-Q filings from Telomir Pharmaceuticals, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Telomir Narrows Loss to $8.35M, Boosts Cash with $8.55M Financing — Nov 10, 2025 Risk: high
Telomir Pharmaceuticals, Inc. (TELO) reported a net loss of $8.35 million for the nine months ended September 30, 2025, a significant improvement from the $13.6
Telomir Pharmaceuticals Files 10-Q for Q2 2025 — Aug 14, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company, based in Miami, FL, operates in the pharmaceutical preparations s
Telomir Pharmaceuticals Files Q1 2025 10-Q — May 14, 2025 Risk: medium
Telomir Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in Miami, Florida, operates in the pharmaceuti
Telomir Pharmaceuticals Files Q3 2024 10-Q — Nov 12, 2024 Risk: low
Telomir Pharmaceuticals, Inc. filed a 10-Q for the period ending September 30, 2024. The company, incorporated in Florida, operates in the pharmaceutical prepar
Telomir Pharmaceuticals Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
Telomir Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company, located at 900 West Platt Street, Suite 200, Tampa, FL 33606, ope
Telomir Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
Telomir Pharmaceuticals, Inc. (TELO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Telomir Pharmaceuticals, Inc. filed a 10-Q report for the per

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX